← Leaderboards
Ryan Bruce Corcoran
Massachusetts General Hospital
$7,598,235
Attributed
$10,976,153
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,296,951 · 9
By mechanism
U54$10,261,512 · 4
R01$4,788,780 · 2
P50$1,350,259 · 2
K08$896,400 · 1
Top collaborators
- Keith T Flaherty13 shared
- Scott Kopetz4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Nabeel Bardeesy$18,920,034
- Dennis Brown$23,445,948
- Ovidiu C Andronesi$8,946,091
- Arnab Chakravarti$9,324,533
- David H Salat$10,570,095
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResponseResistanceMelanomaResistance MechanismTranslational ApproachMap Kinase GeneBiopsySignal TransductionClinical TrialsInhibitor/AntagonistMutationTargeted TreatmentMalignant NeoplasmsMolecularHeterogeneityBraf GenePathway InteractionsPre-ClinicalColorectal CancerMutantCancer PatientMonitorMouse Model
Grant awards (31)
Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer$711,990
R01 · FY2025 · CA · contact PI
Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer$676,391
R01 · FY2024 · CA · contact PI
Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer$697,752
R01 · FY2023 · CA · contact PI
Project 1 - Integrating targeted and immune therapies for BRAF mutant colorectal cancer$313,875
P50 · FY2023 · CA · contact PI
Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer$728,990
R01 · FY2022 · CA · contact PI
Project 1 - Integrating targeted and immune therapies for BRAF mutant colorectal cancer$356,409
P50 · FY2022 · CA · contact PI
An integrated translational approach to overcome drug resistance$1,224,938
U54 · FY2021 · CA · contact PI
Project-003$486,160
U54 · FY2021 · CA · contact PI
Project-002$463,293
U54 · FY2021 · CA · contact PI
Project 1 - Integrating targeted and immune therapies for BRAF mutant colorectal cancer$296,625
P50 · FY2021 · CA · contact PI
Project 2$275,485
U54 · FY2021 · CA · contact PI
An integrated translational approach to overcome drug resistance$1,356,228
U54 · FY2020 · CA · contact PI
Project-003$559,613
U54 · FY2020 · CA · contact PI
Project-002$517,329
U54 · FY2020 · CA · contact PI
Project 2$399,609
U54 · FY2020 · CA · contact PI
Therapeutic resistance and tumor heterogeneity in BRAF mutant colorectal cancer$396,501
R01 · FY2020 · CA · contact PI
Project 1 - Integrating targeted and immune therapies for BRAF mutant colorectal cancer$383,350
P50 · FY2020 · CA · contact PI
An integrated translational approach to overcome drug resistance$1,239,225
U54 · FY2019 · CA · contact PI
Project-003$511,159
U54 · FY2019 · CA · contact PI
Project-002$435,748
U54 · FY2019 · CA · contact PI
Therapeutic resistance and tumor heterogeneity in BRAF mutant colorectal cancer$384,605
R01 · FY2019 · CA · contact PI
Project 2$292,318
U54 · FY2019 · CA · contact PI
Therapeutic resistance and tumor heterogeneity in BRAF mutant colorectal cancer$396,501
R01 · FY2018 · CA · contact PI
An integrated translational approach to overcome drug resistance$2,500,407
U54 · FY2017 · CA · contact PI
Therapeutic resistance and tumor heterogeneity in BRAF mutant colorectal cancer$398,025
R01 · FY2017 · CA · contact PI
Combination Therapy to Improve MAPK Pathway Inhibitor Efficacy in BRAF and KRAS M$179,280
K08 · FY2017 · CA · contact PI
Therapeutic resistance and tumor heterogeneity in BRAF mutant colorectal cancer$398,025
R01 · FY2016 · CA · contact PI
Combination Therapy to Improve MAPK Pathway Inhibitor Efficacy in BRAF and KRAS M$179,280
K08 · FY2016 · CA · contact PI
Combination Therapy to Improve MAPK Pathway Inhibitor Efficacy in BRAF and KRAS M$179,280
K08 · FY2015 · CA · contact PI
Combination Therapy to Improve MAPK Pathway Inhibitor Efficacy in BRAF and KRAS M$179,280
K08 · FY2014 · CA · contact PI
Combination Therapy to Improve MAPK Pathway Inhibitor Efficacy in BRAF and KRAS M$179,280
K08 · FY2013 · CA · contact PI